Suboxone tooth decay lawsuit: dental injury claims

Understanding the Suboxone tooth decay lawsuit: what attorneys need to know

Suboxone, a sublingual film containing buprenorphine and naloxone, has been one of the most widely prescribed medications for opioid use disorder (OUD) in the United States. Developed and marketed by Indivior (formerly Reckitt Benckiser Pharmaceuticals), Suboxone has been credited with helping millions of patients manage their opioid dependence. However, a growing body of evidence — culminating in a June 2022 FDA Drug Safety Communication — has revealed that Suboxone and other buprenorphine-containing sublingual and buccal products cause severe dental problems, including tooth decay, cavities, oral infections, and complete tooth loss.

The Suboxone tooth decay lawsuit represents a significant and rapidly growing area of mass tort litigation. Patients who were prescribed Suboxone sublingual film and experienced severe dental injuries are pursuing legal claims against Indivior, alleging that the company knew or should have known about the risk of dental damage and failed to provide adequate warnings to patients and prescribers. For personal injury attorneys, this litigation presents a compelling opportunity with a large potential plaintiff population, strong scientific evidence, and an FDA communication that directly supports the failure-to-warn theory.

The FDA's June 2022 Drug Safety Communication is the cornerstone of Suboxone litigation — it confirms the causal relationship, demonstrates inadequate prior labeling, and provides a clear timeline showing patients were not warned about dental risks.

How Suboxone sublingual film causes severe dental decay

The acidic pH mechanism of dental damage

The primary mechanism by which Suboxone sublingual film causes dental damage is its acidic pH. When Suboxone film is placed under the tongue or against the cheek to dissolve, it creates an acidic environment in the oral cavity. The film's formulation has a pH that falls well below the critical pH threshold (approximately 5.5) at which tooth enamel begins to demineralize. This acidic environment directly attacks tooth enamel, the hard protective outer layer of the teeth, causing erosion that exposes the underlying dentin to bacterial invasion and decay.

Unlike occasional exposure to acidic foods or beverages, Suboxone use involves repeated, prolonged exposure to an acidic substance placed directly against the oral mucosa and tooth surfaces. Patients typically take Suboxone once or twice daily, and the film takes several minutes to dissolve, creating extended periods of acid exposure with each dose. Over weeks, months, and years of daily use, this cumulative acid exposure progressively erodes enamel, leading to widespread decay, tooth fracture, and tooth loss.

Reduced salivary flow and dry mouth

Buprenorphine, the active opioid component in Suboxone, also contributes to dental damage by reducing salivary flow. Saliva serves critical protective functions in the oral cavity: it neutralizes acids, washes away food particles and bacteria, provides minerals for tooth remineralization, and contains antimicrobial enzymes. When salivary flow is reduced (a condition known as xerostomia or dry mouth), the teeth lose these protective mechanisms and become significantly more vulnerable to decay.

The combination of direct acid exposure from the dissolving film and reduced salivary protection from buprenorphine's pharmacological effects creates a two-pronged assault on dental health. This dual mechanism explains why the dental damage associated with Suboxone tends to be more severe and more widespread than damage associated with other common causes of dental erosion.

Pattern of dental injuries in Suboxone patients

The dental injuries associated with Suboxone use follow a characteristic pattern that distinguishes them from ordinary dental disease. Damage typically begins on the lingual (tongue-side) surfaces of the lower teeth and the palatal surfaces of the upper teeth — areas in direct contact with the dissolving film. The decay pattern is often circumferential, affecting the tooth at the gum line and progressing rapidly through the enamel. Multiple teeth are typically affected simultaneously, and the progression can be remarkably rapid.

The FDA Drug Safety Communication: June 2022 warning on dental problems

What the FDA found

On June 22, 2022, the FDA issued a Drug Safety Communication titled “FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain.” The communication reported that the FDA had received 305 cases of dental adverse events associated with buprenorphine-containing medicines dissolved in the mouth, including 131 cases classified as serious. The reported dental problems included dental caries (cavities), tooth fractures, tooth loss, and the need for dental procedures including extractions, root canals, dental implants, and dentures.

The FDA noted that dental problems were reported even in patients with no prior history of dental issues and that the time to onset of dental problems ranged from two weeks to years after starting treatment. This acknowledgment by the FDA that dental damage occurred even in patients with previously healthy teeth directly supports the plaintiffs' contention that Suboxone causes dental injury rather than merely coinciding with it.

Required label changes

Following the Drug Safety Communication, the FDA required manufacturers of buprenorphine-containing sublingual and buccal products to add new warnings about the risk of dental problems to their product labels. The updated labeling includes information about the risk of dental caries, erosion, and tooth loss; recommends that patients undergo a dental examination before starting treatment; advises patients to continue regular dental visits and report any dental problems; and instructs patients not to brush their teeth immediately after dissolving the film.

Indivior: the manufacturer behind Suboxone and its failure to warn

Corporate history and product development

Indivior PLC (originally a division of Reckitt Benckiser) is the primary manufacturer of Suboxone. The company developed the sublingual film formulation of Suboxone as a successor to the original Suboxone sublingual tablet, transitioning the market from tablets to film through strategic patent management and marketing. The film formulation, which became the dominant form of Suboxone prescribed in the United States, is the specific product at the center of the dental injury litigation.

Indivior's corporate history includes a troubled regulatory record. In 2020, Indivior Inc. (the U.S. subsidiary) pleaded guilty to a federal felony charge related to the fraudulent marketing of Suboxone Film. The company admitted to making misleading claims about the safety of Suboxone Film compared to Suboxone Tablets. This criminal history may be relevant to the dental injury litigation as it demonstrates a pattern of prioritizing market share over accurate safety communication.

What Indivior knew about dental risks

Plaintiffs in Suboxone tooth decay lawsuits allege that Indivior knew or should have known about the dental risks associated with its product well before the FDA's 2022 warning. This allegation is supported by several factors: the acidic pH of the film formulation was known from the product's development; the effects of oral acid exposure on tooth enamel are well-established in dental science; adverse event reports submitted to the FDA documented dental problems in Suboxone patients; and the buprenorphine component's effects on salivary flow were documented in pharmacological literature.

Who qualifies for a Suboxone tooth decay lawsuit: screening criteria

Core qualification requirements

To qualify for a Suboxone tooth decay lawsuit, claimants generally must meet the following criteria:

• Suboxone Film prescription: The claimant was prescribed and used Suboxone sublingual film (buprenorphine/naloxone). Claims primarily focus on the film formulation rather than the original tablet formulation.
• Dental injury: The claimant experienced dental problems after beginning Suboxone treatment, including tooth decay/cavities, tooth fractures, tooth loss, dental infections/abscesses, and/or the need for significant dental procedures.
• Temporal relationship: The dental problems developed after the claimant began using Suboxone Film. Cases where the claimant had a documented history of good dental health prior to Suboxone use are particularly strong.
• Minimum injury threshold: The dental injuries are sufficiently severe to warrant litigation. Most screening criteria require evidence of multiple affected teeth, extractions, root canals, dental implants, or dentures.

Strongest case profiles

The most compelling Suboxone tooth decay cases typically involve:

• Patients with documented good dental health before starting Suboxone (pre-Suboxone dental records are valuable evidence)
• Significant dental damage: multiple tooth extractions, full or partial dentures, dental implants, or extensive restorative work
• Dental damage pattern consistent with acid erosion from the sublingual film
• Extended duration of Suboxone use (longer use periods correspond with more severe damage)
• Patients under 50 years old, where severe tooth loss is atypical and more clearly attributable to an exogenous cause
• Cases with well-documented dental records showing the progression of damage during Suboxone treatment

Damages in Suboxone tooth decay cases: calculating compensation

Economic damages: dental treatment costs

Economic damages in Suboxone tooth decay cases center on the substantial costs of dental treatment and restoration. These costs include emergency dental treatment for acute decay, infections, and fractures; tooth extractions (which can cost hundreds to over a thousand dollars per tooth); root canal therapy; dental implants (typically $3,000 to $6,000 per implant); dental bridges and crowns; full or partial dentures; bone grafting procedures required before implant placement; and ongoing maintenance and replacement of dental prosthetics over the patient's lifetime.

Non-economic damages

Non-economic damages in Suboxone cases include the physical pain and suffering associated with dental decay, infections, and surgical procedures; emotional distress and embarrassment from tooth loss; dietary limitations imposed by the inability to chew properly; speech difficulties associated with missing teeth or ill-fitting dentures; and the psychological impact of disfigurement in a population already managing the challenges of opioid recovery.

The emotional component of dental damage is particularly significant because many Suboxone patients undertook treatment to improve their lives by overcoming opioid addiction. To suffer disfiguring dental damage as a consequence of treatment intended to help them represents a profound betrayal of trust, and juries may find this narrative particularly compelling.

Punitive damages considerations

Given the allegations that Indivior was aware of dental risks and chose not to warn patients, punitive damages may be available in jurisdictions that permit them. Indivior's criminal conviction for fraudulent marketing practices, combined with evidence of internal knowledge about dental risks, could support findings of willful, wanton, or reckless conduct.

Building a strong Suboxone case: litigation strategies for PI attorneys

Medical and dental record collection

Building a strong Suboxone tooth decay case requires comprehensive record collection. Attorneys should obtain prescription records confirming Suboxone Film prescriptions (pharmacy dispensing records, prescriber records, insurance claim records); pre-Suboxone dental records establishing baseline dental health; dental records during and after Suboxone use showing the progression of decay; dental treatment records including all procedures performed; and medical records related to Suboxone treatment.

Pre-Suboxone dental records are particularly valuable because they establish that the patient had reasonable dental health before starting the medication, undermining the defense argument that dental problems were attributable to pre-existing conditions or lifestyle factors.

Expert witness development

Key expert categories for Suboxone tooth decay cases include:

• Forensic dentists: To examine the pattern of dental damage and opine that it is consistent with acid erosion from sublingual film exposure rather than other causes.
• Pharmacologists: To explain the mechanisms by which Suboxone Film causes dental damage, including the acidic pH and salivary reduction effects.
• Regulatory experts: To testify about the adequacy of Suboxone's labeling and the significance of the FDA's 2022 Drug Safety Communication.
• Dental economists or life care planners: To quantify current and future dental treatment costs, including ongoing prosthetic maintenance and replacement.
• Addiction medicine specialists: To provide context about the OUD treatment landscape and why patients relied on Suboxone without awareness of dental risks.

The opioid crisis context: why Suboxone patients deserve justice

The Suboxone tooth decay litigation exists within the broader context of the opioid crisis. Millions of Americans became dependent on opioids through legally prescribed medications, and medication-assisted treatment (MAT) with products like Suboxone has been recognized as the gold standard for managing opioid use disorder. Patients who turned to Suboxone were seeking to rebuild their lives and overcome addiction. They trusted that their medication was safe and that their healthcare providers had access to complete safety information.

The failure to warn these vulnerable patients about a foreseeable and preventable complication is particularly egregious because it undermined their recovery efforts. Dental damage caused embarrassment, pain, and financial hardship during a period when patients needed stability and support. Juries are likely to be sympathetic to plaintiffs who can demonstrate that they sought treatment to improve their lives and were harmed by a product they trusted.

Statute of limitations in Suboxone tooth decay claims

Statute of limitations analysis in Suboxone cases must consider the date of injury (when dental damage first manifested), the discovery rule (when the patient knew or should have known that Suboxone caused their dental problems), and the applicable state statute of limitations period. Because the FDA did not issue its dental warning until June 2022, many patients did not connect their dental problems to Suboxone until after that date, even if the dental damage began years earlier.

The discovery rule may toll the statute of limitations in many cases, extending the filing deadline to a point after the patient became aware of the Suboxone-dental damage connection. However, statutes of limitations vary significantly by state, and attorneys should conduct a jurisdiction-specific analysis for each potential claim.

Comparative analysis: Suboxone litigation in the mass tort landscape

The Suboxone tooth decay litigation can be compared to other pharmaceutical mass torts where a manufacturer failed to disclose a known product risk. Like the Depo-Provera meningioma litigation, it involves a widely prescribed medication where the manufacturer had knowledge of a specific risk and failed to warn. Like the NEC baby formula litigation, it involves a product used by a vulnerable population who relied on the manufacturer's safety representations.

A distinguishing feature of Suboxone litigation is the clarity and accessibility of the injury. Dental damage is visible, tangible, and understandable to jurors in a way that some other mass tort injuries are not. Photographs of dental destruction, before-and-after dental records, and the testimony of patients who lost their teeth while trying to overcome addiction create a compelling courtroom narrative.